A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy.
Anna C. Ferrari
No relevant relationships to disclose
Mark N. Stein
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Alejandro Gomez-Pinillos
No relevant relationships to disclose
Donna D. Catamero
No relevant relationships to disclose
Tina M. Mayer
No relevant relationships to disclose
Fiona Collins
No relevant relationships to disclose
Tomasz M. Beer
No relevant relationships to disclose
Robert S. DiPaola
No relevant relationships to disclose